Trial Profile
The prospective, single-arm, single-center, exploratory clinical study of Apatinib combined with Tegafur Gimeracil Oteracil Potassium Capsule in treating patients with Advanced esophageal squamous carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2019
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Rivoceranib (Primary)
- Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2019 Interim results (n=15) assessing clinical efficacy and safety of apatinib combined with Gimeracil/oteracil/tegafur in patients with advanced esophageal squamous cell carcinoma published in the Investigational New Drugs
- 03 Oct 2017 New trial record